Hodgkin lymphoma: Response assessment by Revised International Workshop Criteria

References

• Jochelson M, Mauch P, Balikan J, Rosenthal D, Canellos G. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 1985; 3: 637–640
   PubMed Web of Science ®Google Scholar
• Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci A A, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 1998; 16: 818–829
   PubMed Web of Science ®Google Scholar
• Meyer R M, Gospodarowicz M K, Connors J M, Pearcey R G, Bezjak A, Wells W A, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 4634–4642
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Eghbali H, Brice P, Creemers G Y, Van Marwijk Kooij M, Carde P, Van’t Veer M B, et al. Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-F trial. Blood 2005; 106, (abstr. 814)
   Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol 2001; 19: 414–419
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte M F, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed classical computed tomography scan imaging. Blood 1999; 94: 429–433
   PubMed Web of Science ®Google Scholar
• Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793–800
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Fanti S, Battista G, Tani M, Castellucci P, Stefoni V, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004; 91: 850–854
   PubMed Web of Science ®Google Scholar
• Mikhaeel N G, Timothy A R, O'Doherty M J, Hain S, Maisey M N. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 2000; 39: 543–553
   PubMed Web of Science ®Google Scholar
• Cheson B D, Pfistner B, Juweid M E, Gascoyne R D, Specht L, Horning S J, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25(5)579–586
   PubMed Web of Science ®Google Scholar
• Juweid M E, Stroobants S, Hoekstra O S, Mottaghy F M, Dietlein M, Guermazi, et al. Use of positron emission tomography (PET) for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project (IHP) in Lymphoma. J Clin Oncol 2007; 25(5)571–578
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. Br J Haematol 2001; 115: 272–278
   PubMed Web of Science ®Google Scholar
• Armitage J. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005; 55: 368–376
   PubMed Web of Science ®Google Scholar
• Horning S J, Williams J, Bartlett N L, Bennett J M, Hoppe R T, Neuberg D, et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 2000; 18: 972–980
   PubMed Web of Science ®Google Scholar
• Glick J H, Young M L, Harrington D, Schilsky R L, Beck T, Neiman R, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998; 16: 19–26
   PubMed Web of Science ®Google Scholar
• Kaplan E S, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 58: 457–481
   Google Scholar
• Hueltenschmidt B, Sautter-Bihl M L, Lang O, Maul F D, Fischer J, Mergenthaler H G, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001; 91: 302–310
   PubMed Web of Science ®Google Scholar
• Weihrauch M R, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930–2934
   PubMed Web of Science ®Google Scholar
• de Wit M, Bohuslavizki K H, Buchert R, Bumann D, Clausen M, Hossfeld D K. 18FDG-PET following treatment as valid predictor for disease-free survival I Hodgkin's disease. Ann Oncol 2001; 12: 29–37
   PubMed Web of Science ®Google Scholar
• Lavely W C, Delbeke D, Greer J P, Morgan D S, Byrne D W, Price R R, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 307–315
   PubMed Web of Science ®Google Scholar
• Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003; 44: 1225–1231
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte M F, Belhocine T, Hustinx R, Rigo P, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14: 123–130
   PubMed Web of Science ®Google Scholar
• Friedberg J W, Fischman A, Neuberg D, Kim H, Takvorian T, Ng A K, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004; 45: 85–92
   PubMed Web of Science ®Google Scholar
• Panizo C, Perez-Salazar M, Bendandi M, Rodriguez-Calvillo M, Boan J F, Garcia-Velloso M J, et al. Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma 2004; 45: 1829–1833
   PubMed Web of Science ®Google Scholar